Nothing Special   »   [go: up one dir, main page]

Vera, 2017 - Google Patents

Peptide-Based Strategies of Delivering Semiconductor Nanocrystals into Living Cells

Vera, 2017

View PDF
Document ID
11114139279910071004
Author
Vera C
Publication year

External Links

Snippet

Semiconductor nanocrystals or quantum dots (QDs) possess exceptional optical and physicochemical properties, for instance, their brightness and long fluorescence lifetimes, which makes them valuable for live-cell imaging. Due to their large size, QDs do not cross …
Continue reading at indigo.uic.edu (PDF) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A61K47/48238—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying agent being a protein, peptide, polyamino acid
    • A61K47/48246—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying agent being a protein, peptide, polyamino acid drug-peptide, protein or polyamino acid conjugates, i.e. the modifying agent being a protein, peptide, polyamino acid which being linked/complexed to a molecule that being the pharmacologically or therapeutically active agent
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A61K47/48007—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the pharmacologically- or therapeutically-active agent being covalently bound or complexed to a modifying agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A61K47/48769—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form
    • A61K47/48792—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form the form being a colloid, emulsion, i.e. having at least a dispersed/continuous oil phase and a dispersed/continuous aqueous phase, dispersion or suspension

Similar Documents

Publication Publication Date Title
Zong et al. Peptide-functionalized gold nanoparticles: versatile biomaterials for diagnostic and therapeutic applications
Field et al. Peptides for specifically targeting nanoparticles to cellular organelles: quo vadis?
Medintz et al. Intracellular delivery of quantum dot− protein cargos mediated by cell penetrating peptides
Wu et al. Development of viral nanoparticles for efficient intracellular delivery
Chen et al. Transmembrane delivery of the cell-penetrating peptide conjugated semiconductor quantum dots
Boeneman et al. Selecting improved peptidyl motifs for cytosolic delivery of disparate protein and nanoparticle materials
Martín et al. Design, synthesis and characterization of a new anionic cell‐penetrating peptide: SAP (E)
Wang et al. Peptide‐engineered fluorescent nanomaterials: Structure design, function tailoring, and biomedical applications
US8859284B2 (en) Delivery of nanoparticles to neurons
Delehanty et al. Delivering quantum dot-peptide bioconjugates to the cellular cytosol: escaping from the endolysosomal system
Brunetti et al. Near-infrared quantum dots labelled with a tumor selective tetrabranched peptide for in vivo imaging
Breger et al. Nanoparticle cellular uptake by dendritic wedge peptides: achieving single peptide facilitated delivery
Zhang et al. Enhanced cellular entry and efficacy of tat conjugates by rational design of the auxiliary segment
Park et al. Cell-selective intracellular drug delivery using doxorubicin and α-helical peptides conjugated to gold nanoparticles
Tian et al. Advances in cell penetrating peptides and their functionalization of polymeric nanoplatforms for drug delivery
So et al. HaloTag protein-mediated specific labeling of living cells with quantum dots
Wang et al. A quantitative study of the intracellular fate of pH-responsive doxorubicin-polypeptide nanoparticles
US20130158244A1 (en) Modular Functional Peptides for the Intracellular Delivery of Nanoparticles
Bayles et al. Rapid cytosolic delivery of luminescent nanocrystals in live cells with endosome-disrupting polymer colloids
Panigrahi et al. Cyclic peptide-based nanostructures as efficient siRNA carriers
Allen et al. Hydrophobicity is a key determinant in the activity of arginine-rich cell penetrating peptides
Falciani et al. Nanoparticles exposing neurotensin tumor‐specific drivers
Burns et al. Cellular delivery of doxorubicin mediated by disulfide reduction of a peptide-dendrimer bioconjugate
Dmitriev et al. Metallochelate coupling of phosphorescent Pt-porphyrins to peptides, proteins, and self-assembling protein nanoparticles
Arafiles et al. Cell-surface-retained peptide additives for the cytosolic delivery of functional proteins